Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DNA X, Inc.SONM · Entity 8261 | See Remarks | April 23, 2025 | April 25, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DNA X, Inc.
Report date April 23, 2025 · Filed April 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,668 |
Reported balance
After 2025-04-23 transaction · row 1
1 source rowRow 1 · 2025-04-23 · Sale · Disposed 31,326 · Balance 62,668 F1: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are mandated by the Issuer's election under its equity incentive plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.43 to $1.45, inclusive. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a securityholder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are mandated by the Issuer's election under its equity incentive plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.43 to $1.45, inclusive. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a securityholder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 23, 2025 Filed Apr 25, 2025 12:35 UTC | DNA X, Inc. SONM · Entity 8261 | SaleCommon Stock | 31,326 | $1.45 | $45,422.70 |
DisclosureSEC source: 0001641172-25-006115 · ownership.xml · nonDerivative · entry 1 Becher Charles · CIK 0001775310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,668 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are mandated by the Issuer's election under its equity incentive plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.43 to $1.45, inclusive. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a securityholder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 06, 2025 Filed Feb 11, 2025 02:30 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 70,671 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-005764 · ownership.xml · nonDerivative · entry 1 Becher Charles · CIK 0001775310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,994 F1 · shares: Represents the grant of restricted stock units that vest in two equal installments on the 90th and 180th day following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Consists of (i) 23,323 shares of common stock and (ii) 70,671 unvested restricted stock units. F3 · balance_after: The number of securities reported herein reflects the effects of a 1-for-10 reverse stock split effected by the Issuer on July 17, 2024, which was exempt from reporting pursuant to Rule 16a-9. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 22:30 UTC | DNA X, Inc. SONM · Entity 8261 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001493152-23-046419 · ownership.xml · derivative · entry 2 Becher Charles · CIK 0001775310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 125,000 shares Expires 2032-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options will vest in eleven (11) equal quarterly installments from February 29, 2024 to August 29, 2026. The options become exercisable upon vesting. F1 · balance_after: The options will vest in eleven (11) equal quarterly installments from February 29, 2024 to August 29, 2026. The options become exercisable upon vesting. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 22:30 UTC | DNA X, Inc. SONM · Entity 8261 | Exercise / conversionCommon Stock | 125,000 | $0.42 | $52,375.00 |
DisclosureSEC source: 0001493152-23-046419 · ownership.xml · nonDerivative · entry 1 Becher Charles · CIK 0001775310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 233,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.